PDF(Pubmed)
Abstract：
To retrospectively analyze the efficacy and safety of dupilumab in the treatment of bullous pemphigoid.
From October 2020 to October 2022, the medical records of patients with bullous pemphigoid who were treated with dupilumab in our department were collected retrospectively to analyze the therapeutic effect and changes in laboratory indexes.
The records of a total of 11 patients with bullous pemphigoid who were treated with dupilumab was reviewed. Within 2 weeks of the treatment, 10 (90.9%) of the 11 patients had complete or substantial control of the disease. The BPDAI scores of the patients decreased from baseline 113 (62, 181) to 37 (6, 130) at 2 weeks (p = .001) and 4 (0, 37) at 12 weeks after treatment (p < .001). In the 11 patients treated with dupilumab, the relief time of pruritus was 0-3 days (0.5, 7) days, and the pruritus was significantly alleviated after 2 weeks (t = 15.925, p < .001). The DLQI score decreased from (25.5 ± 2.5) before treatment, to (11.8 ± 4.4) at 2 weeks (t = 10.764, p < .001) and (2.1 ± 1.9) at 12 weeks (t = 30.038, p < .001). The patients had high eosinophil counts, high serum IgE levels, low serum total protein levels, and abnormal blood coagulation function. The aforementioned indicators gradually returned to normal after treatment. No adverse reactions occurred during the treatment.
Dupilumab can effectively control the condition of bullous pemphigoid, efficiently relieve pruritus symptoms, and is relatively safe.
From October 2020 to October 2022, the medical records of patients with bullous pemphigoid who were treated with dupilumab in our department were collected retrospectively to analyze the therapeutic effect and changes in laboratory indexes.
The records of a total of 11 patients with bullous pemphigoid who were treated with dupilumab was reviewed. Within 2 weeks of the treatment, 10 (90.9%) of the 11 patients had complete or substantial control of the disease. The BPDAI scores of the patients decreased from baseline 113 (62, 181) to 37 (6, 130) at 2 weeks (p = .001) and 4 (0, 37) at 12 weeks after treatment (p < .001). In the 11 patients treated with dupilumab, the relief time of pruritus was 0-3 days (0.5, 7) days, and the pruritus was significantly alleviated after 2 weeks (t = 15.925, p < .001). The DLQI score decreased from (25.5 ± 2.5) before treatment, to (11.8 ± 4.4) at 2 weeks (t = 10.764, p < .001) and (2.1 ± 1.9) at 12 weeks (t = 30.038, p < .001). The patients had high eosinophil counts, high serum IgE levels, low serum total protein levels, and abnormal blood coagulation function. The aforementioned indicators gradually returned to normal after treatment. No adverse reactions occurred during the treatment.
Dupilumab can effectively control the condition of bullous pemphigoid, efficiently relieve pruritus symptoms, and is relatively safe.
摘要：
回顾性分析dupilumab治疗大疱性类天疱疮的疗效和安全性。
回顾性收集2020年10月至2022年10月在我科接受dupilumab治疗的大疱性类天疱疮患者的病历，分析其治疗效果及实验室指标变化。
回顾了总共11例接受dupilumab治疗的大疱性类天疱疮患者的记录。在治疗的2周内，11例患者中有10例（90.9%）完全或基本控制了疾病。患者的BPDAI评分在治疗后2周时从基线113(62,181)降至37(6,130)(p=.001),在治疗后12周时降至4(0,37)(p<.001)。在接受dupilumab治疗的11例患者中，瘙痒缓解时间为0-3天（0.5，7）天，2周后瘙痒明显缓解(t=15.925,p<.001)。DLQI评分从治疗前的(25.5±2.5)分下降,至2周时的（11.8±4.4）（t=10.764，p<.001）和12周时的（2.1±1.9）（t=30.038，p<.001）。患者的嗜酸性粒细胞计数较高，高血清IgE水平，低血清总蛋白水平，凝血功能异常。治疗后上述指标逐渐恢复正常。治疗过程中无不良反应发生。
Dupilumab能有效控制大疱性类天疱疮的病情，有效缓解瘙痒症状，相对安全。
回顾性收集2020年10月至2022年10月在我科接受dupilumab治疗的大疱性类天疱疮患者的病历，分析其治疗效果及实验室指标变化。
回顾了总共11例接受dupilumab治疗的大疱性类天疱疮患者的记录。在治疗的2周内，11例患者中有10例（90.9%）完全或基本控制了疾病。患者的BPDAI评分在治疗后2周时从基线113(62,181)降至37(6,130)(p=.001),在治疗后12周时降至4(0,37)(p<.001)。在接受dupilumab治疗的11例患者中，瘙痒缓解时间为0-3天（0.5，7）天，2周后瘙痒明显缓解(t=15.925,p<.001)。DLQI评分从治疗前的(25.5±2.5)分下降,至2周时的（11.8±4.4）（t=10.764，p<.001）和12周时的（2.1±1.9）（t=30.038，p<.001）。患者的嗜酸性粒细胞计数较高，高血清IgE水平，低血清总蛋白水平，凝血功能异常。治疗后上述指标逐渐恢复正常。治疗过程中无不良反应发生。
Dupilumab能有效控制大疱性类天疱疮的病情，有效缓解瘙痒症状，相对安全。
